Navigation Links
Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Date:4/26/2009

WAYNE, N.J. and EMERYVILLE, Calif., April 27 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial evaluating Nexavar(R) (sorafenib) tablets in patients with unresectable stage III or stage IV melanoma was stopped early following a planned interim analysis by the independent Data Monitoring Committee (DMC). The trial was sponsored by the National Cancer Institute (NCI) and led by the Eastern Cooperative Oncology Group (ECOG) under a Clinical Trials Agreement between NCI and Bayer and Onyx. The DMC concluded that the study would not meet the primary endpoint of improved overall survival among patients receiving Nexavar in combination with the chemotherapeutic agents carboplatin and paclitaxel versus patients receiving placebo plus the chemotherapeutic agents. The treatment effect was comparable in each arm. The DMC also reported that there were no unexpected serious side effects, though the final analysis of the data will occur per protocol and statistical analysis plan.

Bayer and Onyx will further review the findings of this analysis to determine what, if any, impact these data might have on other ongoing Nexavar melanoma trials. Data from this study are expected to be presented at an upcoming scientific meeting.

"We're disappointed with the results of the study and that the therapy did not bring benefit to patients with melanoma, a historically difficult tumor to treat," said Todd Yancey, M.D., vice president of clinical development at Onyx. "Onyx and Bayer remain committed to our broad clinical program to investigate the potential of Nexavar in a wide range of cancers, and we intend to build upon the success of Nexavar in our approved indications in hepatocellular carcinoma (liver cancer) and advanced renal cell carcinoma (kidney cancer
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
4. Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
7. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
8. Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin
9. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
10. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015 Sleep ... sleep therapy, and HGE Health Care Solutions, a ... announced today a comprehensive sleep management and cost ... (OSA). OSA is a chronic medical ... sleep and may increase a patient,s risk for ...
(Date:9/1/2015)... 1, 2015   Millstone Medical Outsourcing announced today ... in Olive Branch, MS. Now totaling ... facility has added the capacity required to meet the ... "This expansion gives us the opportunity to grow in parallel ... Millstone MS. "Two and a half years ago we were ...
(Date:9/1/2015)... Belgium , Sept. 1, 2015 VolitionRx ... on developing blood-based diagnostic tests for a broad range of ... Executive Officer, Cameron Reynolds , is scheduled to attend ... is being held September 9-10, 2015 in Boston, ... on September 10. Wells Fargo Securities Research ...
Breaking Medicine Technology:Sleep Specialists, LLC and HGE Health Care Solutions Announce Comprehensive Sleep Program 2Millstone Medical Outsourcing Announces Olive Branch Expansion 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 2VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 3VolitionRx to Attend 10th Annual Wells Fargo Healthcare Conference on September 9-10, 2015 4
... in Ohio supported by the biopharmaceutical research sector would ... new taxes in the Medicare prescription drug program – ... to technical work, manufacturing to construction and other building ... sector supports a broad array of high-quality jobs. ...
... Sept. 27, 2011 Visiting Nurse Services of ... home health agencies, announces that it has entered ... advanced home telehealth technology to patients with chronic ... Experts in Telehealth(SM), is a world class developer, ...
Cached Medicine Technology:Research Demonstrates Possible Ohio Job Losses from Sectors Supported by Biopharmaceutical Companies 2Research Demonstrates Possible Ohio Job Losses from Sectors Supported by Biopharmaceutical Companies 3Visiting Nurse Services of Connecticut Selects Cardiocom® As Its New Telehealth Vendor 2
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Horizon Blue ... the 50 Best Companies for Latinas in the LATINA Style 50 Report that recognizes ... , For 2015, Horizon BCBSNJ climbs from number 24 to 21 ...
(Date:9/1/2015)... Jose, CA (PRWEB) , ... September 01, 2015 ... ... cross-device computing and collaboration, announces Splashtop Business for Remote Support , a ... remote support solution. Unhappy with the escalating renewal prices and inadequate customer ...
(Date:9/1/2015)... (PRWEB) , ... September 01, ... ... Professional Background Screeners (NAPBS®) has announced that Edge Information Management has ... by the Background Screening Credentialing Council (BSCC). , “Achieving and maintaining ...
(Date:9/1/2015)... ... September 01, 2015 , ... e-Spirit ... version 5.2 of the FirstSpirit Content Management System with new capabilities and enhancements ... version of FirstSpirit, companies will be well on their way to achieving digital ...
(Date:9/1/2015)... ... , ... Two of Washington D.C.’s most respected chefs are using their global ... Recently named “the next big thing” in the culinary world by Elle Spain, award-winning ... behind food and reclaiming culinary traditions on the brink of extinction. According to Amy ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4
... tumor cells can be lulled to sleep by a factor ... this week in the Journal of Experimental Medicine ... prostate cancer patients after treatment, often as a result of ... and colleagues at Southern Illinois University School of Medicine now ...
... PROVIDENCE, R.I. [Brown University] It,s no wonder that medicine,s ... arms race. When new drugs are developed to combat infections, ... A particularly ingenious weapon in the bacterial arsenal is the ... membranes of bacteria that can recognize and expel drugs that ...
... make use of recent experiences. Scientists from Ludwig-Maximilians-Universitt ... asked test subjects to estimate distances in a ... tended to approach the mean of all previously ... able to accurately predict the experimental findings using ...
... who have frequent bouts of wheezing with a daily dose ... But results of a recent study are likely to change ... at Washington University School of Medicine in St. Louis, found ... wheezing episodes than treating the child with higher doses of ...
... VOICE, an HIV prevention trial that has been evaluating ... HIV in women daily use of one of two ... stopped testing the gel. The decision to discontinue use of ... a routine review of study data concluded tenofovir gel was ...
... News) -- A condition called non-alcoholic fatty liver disease (NAFLD) ... new study finding that surprised Johns Hopkins researchers. It,s ... obesity and heart disease -- had a detrimental impact on ... does not affect survival. "Physicians have considered fatty liver ...
Cached Medicine News:Health News:New compound defeats drug-resistant bacteria 2Health News:New compound defeats drug-resistant bacteria 3Health News:When errors improve performance: Model describes how experiences influence our perception 2Health News:Daily wheezing treatment no different from intermittent in toddlers 2Health News:Daily wheezing treatment no different from intermittent in toddlers 3Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 2Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 3Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 4Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 5Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 6Health News:Tenofovir gel dropped from HIV prevention trial in women because it was not effective 7Health News:Fatty Liver Disease Doesn't Affect Survival, Study Finds 2
... The CSV-1000CVA20/30 test face provides three contrast ... acuity from 20/16 to 20/100. This test is ... such as associated with contact lens evaluation or ... of the test provide the same contrast and ...
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
Contrast sensitivity testing, glare sensitivity testing and ETDRS acuity testing are provided in the self standardized CSV-1000 instrument. Patented photocell circuitry automatically monitors and cal...
... Sample of Topics Covered: diagrams, ... tx's and differentials of a ... eyes, vision loss, pupillary abnormalities, ... infections, medications, cataracts, vision correction ...
Medicine Products: